Evidence map›Paper›PMID 28645942›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017

Mutational Heterogeneity in

Mireia Gausachs, Ester Borras, Kyle Chang, Sara Gonzalez, Daniel Azuara, Axel Delgado Amador, Adriana Lopez-Doriga, F Anthony San Lucas, Xavier Sanjuan, Maria J Paules and 14 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Polyclonal origins of human premalignant colorectal lesions.bioRxiv : the preprint server for biology · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Colorectal Cancer: Risk Factors, Novel Approaches in Molecular Screening and Treatment.International journal of molecular and cellular medicine · 2025
    Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Gut microbiota-derived metabolites in CRC progression and causation.Journal of cancer research and clinical oncology · 2021
    Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 2 institutions in 1 country.

Mireia GausachsHereditary Cancer Program, Catalan Institute of Oncology (ICO - IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Ester BorrasDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Kyle ChangDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Sara GonzalezHereditary Cancer Program, Catalan Institute of Oncology (ICO - IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Daniel AzuaraHereditary Cancer Program, Catalan Institute of Oncology (ICO - IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Axel Delgado AmadorDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Adriana Lopez-DorigaCancer Prevention and Control Program, Catalan Institute of Oncology (ICO-IDIBELL) and CIBERESP, L'Hospitalet de Llobregat, Barcelona, Spain.
F Anthony San LucasDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Xavier SanjuanDepartment of Pathology, University Hospital Bellvitge (HUB - IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Maria J PaulesDepartment of Pathology, University Hospital Bellvitge (HUB - IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Melissa W TaggartDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Gareth E DaviesAvera Institute for Human Genetics, Sioux Falls, South Dakota.
Erik A EhliAvera Institute for Human Genetics, Sioux Falls, South Dakota.
Jerry FowlerDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Victor MorenoCancer Prevention and Control Program, Catalan Institute of Oncology (ICO-IDIBELL) and CIBERESP, L'Hospitalet de Llobregat, Barcelona, Spain.
Marta PinedaHereditary Cancer Program, Catalan Institute of Oncology (ICO - IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Y Nancy YouDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Patrick M LynchClinical Cancer Genetics Program, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Conxi LazaroHereditary Cancer Program, Catalan Institute of Oncology (ICO - IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Nicholas E NavinGraduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Paul A ScheetGraduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ernest T HawkDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Gabriel CapellaHereditary Cancer Program, Catalan Institute of Oncology (ICO - IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain. EVilar@mdanderson.org gcapella@iconcologia.net.
Eduardo VilarDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas. EVilar@mdanderson.org gcapella@iconcologia.net.
Instituto de Salud Carlos III · ESCentro de Investigación Biomédica en Red de Cáncer · ES

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
R25 SUPPLEMENT IN GENETIC EPIDEMIOLOGY EDUCATIONR25CA057730 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHANG, SHINE · 1992 to 2016
$18.6M
PAARK4Kids-Pharmacogenomics of Anticancer Agents Research in ChildrenU01GM092666 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI RELLING, MARY V · 2010 to 2014
$8.9M
Statistical Methods for Population Genomics and "Next-gen" Sequencing DataR01HG005859 · NHGRI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SCHEET, PAUL A · 2011 to 2015
$1.9M
Discovering New Targets for Chemoprevention in Familial Adenomatous PolyposisR03CA176788 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI VILAR SANCHEZ, EDUARDO · 2014 to 2015
$160k
NCI NIH HHS P30 CA016672NCI NIH HHS R03 CA176788NCI NIH HHS R25 CA057730NHGRI NIH HHS R01 HG005859NIGMS NIH HHS U01 GM092666
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Adenomatous Polyposis Coli ProteinBiopsyCarcinogenesisCarcinomaClonal EvolutionColorectal NeoplasmsFemaleGenetic HeterogeneityGenotypeHigh-Throughput Nucleotide SequencingHumansMaleMutationProto-Oncogene Proteins p21(ras)Adenomatous Polyposis Coli ProteinKRAS protein, humanProto-Oncogene Proteins p21(ras)

Identifiers

PMID28645942
PMCPMC5626604
OpenAlexW2719863564

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.